Ariad Pharmaceuticals Inc. (ARIA)
-NasdaqGS 17.79 
0.03(0.14%) 04:00 SGT|After Hours
:
17.80 0.01 (0.08%) 04:29 SGT
| Prev Close: | 17.81 |
|---|
| Open: | 17.92 |
|---|
| Bid: | 17.51 x 500 |
|---|
| Ask: | 18.24 x 500 |
|---|
| 1y Target Est: | 27.72 |
|---|
| Beta: | 1.57 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 17.43 - 17.99 |
|---|
| 52wk Range: | 15.35 - 25.40 |
|---|
| Volume: | 814,767 |
|---|
| Avg Vol (3m): | 3,152,770 |
|---|
| Market Cap: | 3.28B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.36 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ARIAD Honored with Gold Stevie® Awards as Pharmaceutical Company of the Year at 2013 American Business AwardsBusiness Wire(Wed, 05:00 SGT)
- Ariad's Iclusig in GIST Phase II StudyZacks(Wed, 03:30 SGT)
- 1 Thing You Always Wanted to Know About Drugs (but Were Afraid to Ask)at Motley Fool(Sun, 16 Jun)
- ARIAD Announces Webcast of Its Annual Shareholders MeetingBusiness Wire(Thu, 13 Jun)
- Ariad Pharmaceuticals Inc. Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 02:40 PMat Seeking Alpha(Wed, 12 Jun)
- 4 Healthcare Stock Stories For Thursday Inspectionat Wall St. Cheat Sheet(Wed, 12 Jun)
- Ash Stevens to Manufacture Ponatinib APIMarketwired(Tue, 11 Jun)
- ARIAD Announces Initiation of Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal TumorsBusiness Wire(Tue, 11 Jun)
- Ariad dips as analyst lowers lung cancer drug viewAP(Tue, 11 Jun)
- Ariad dips as analyst lowers lung cancer drug viewAP(Tue, 11 Jun)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 473.90 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.67 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.40 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | -1.08 |
|---|
Business Summary
ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing addition...
View More